サマリー

市場展望（MARKET OUTLOOK
Triton Market Researchの調査によると、世界の免疫グロブリン市場は、2022年から2028年の予測期間においてCAGR 6.77%で上昇傾向を示すと示唆されています。
市場の成長は、世界の老人人口の増加、加齢関連疾患の発生率の増加、自己免疫疾患の流行、研究開発活動の増加、免疫不全疾患の流行などの推進力によって支えられています。一方、免疫グロブリン療法に関連する高価格や、その使用による副作用のリスクの高さは、市場の成長を阻害する要因となっています。
一方、静脈内免疫グロブリン（IVIG）治療の採用が進み、臨床試験の実施件数が増加していることから、免疫グロブリン市場の見通しは全体的に明るいといえます。
地域別展望
免疫グロブリン市場は、北米、アジア太平洋、欧州、中南米、中東、アフリカを対象としています。
北米は免疫グロブリン市場の世界的なリーダーであり、予測期間終了までその優位性を維持すると予想されます。この地域には、Pfizer Inc、CSL Behring、ADMA Biologicsなどのトップ企業が存在し、市場の成長を支えています。
また、米国とカナダでは様々な疾患の発生率が高いため、免疫グロブリン市場は免疫グロブリンの使用量が増加する機会を提供しています。さらに、米国食品医薬品局による製品認可の増加により、この地域における免疫グロブリン製品の需要と採用が増加すると予想されています。
競合の見通し
世界の免疫グロブリン市場に掲載されている主なプレーヤーには、Pfizer Inc、Bio Products Laboratory、Grifols SA、Octapharma AG、China Biologic Products Inc、ADMA Biologics、Sichuan Yuanda Shuyang Pharmaceutical Co Ltd、CSL Behring、Kedrion Biopharma、Kamada Ltd、LFB Group、Sankin Plasma Products BV、Shanghai RAAS Blood Products Co Ltd、武田薬品工業株式会社および Biotest AGがあります。
Biotest AGは、血漿タンパク質製品や生物治療薬を供給する世界的に有名な企業です。同社の製品は、主に血液学、臨床免疫学、急性期医療に利用されています。同社のバリューチェーンは、前臨床・臨床開発からマーケティング、流通に至るまで多岐にわたります。Biotest AGは、ヒト血漿から得られるアルブミン、凝固因子、免疫グロブリンを製造しています。1946年に設立され、現在、世界90カ国以上で製品を販売しています。Biotest AGは、自社の子会社を通じて直接販売するか、地域の代理店やマーケティングパートナーとともに商品を販売しています。

ページTOPに戻る

目次

TABLE OF CONTENTS
1. GLOBAL IMMUNOGLOBULIN MARKET – SUMMARY
2. INDUSTRY OUTLOOK
2.1. IMPACT OF COVID-19 ON THE IMMUNOGLOBULIN MARKET
2.2. KEY INSIGHTS
2.2.1. DEVELOPMENT OF NEW PURIFICATION METHODS
2.2.2. INCREASING PREFERENCE FOR PERSONALIZED MEDICINES
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTES
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. THREAT OF COMPETITIVE RIVALRY
2.4. MARKET ATTRACTIVENESS INDEX
2.5. VENDOR SCORECARD
2.6. KEY MARKET STRATEGIES
2.6.1. PRODUCT LAUNCHES & DEVELOPMENTS
2.6.2. PARTNERSHIPS & AGREEMENTS
2.7. MARKET DRIVERS
2.7.1. GROWTH IN THE GERIATRIC POPULATION
2.7.2. PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS
2.7.3. INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
2.8. MARKET CHALLENGES
2.8.1. HIGH COST OF THERAPY
2.8.2. HIGH RISK OF SIDE EFFECTS DUE TO THE USE OF IMMUNOGLOBULIN
2.9. MARKET OPPORTUNITIES
2.9.1. INCREASING ADOPTION OF INTRAVENOUS IMMUNOGLOBULIN (IVIG) TREATMENTS
2.9.2. GROWING CLINICAL TRIALS
3. GLOBAL IMMUNOGLOBULIN MARKET OUTLOOK – BY TYPE
3.1. IGG
3.2. IGA
3.3. IGM
3.4. IGE
3.5. IGD
4. GLOBAL IMMUNOGLOBULIN MARKET OUTLOOK – BY DELIVERY MODE
4.1. INTRAVENOUS
4.2. SUBCUTANEOUS
4.3. INTRAMUSCULAR
5. GLOBAL IMMUNOGLOBULIN MARKET OUTLOOK – BY APPLICATION
5.1. HYPOGAMMA GLOBULINEMIA
5.2. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
5.3. PRIMARY IMMUNODEFICIENCY DISEASES
5.4. MYASTHENIA GRAVIS
5.5. MULTIFOCAL MOTOR NEUROPATHY
5.6. IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
5.7. INFLAMMATORY MYOPATHIES
5.8. SPECIFIC ANTIBODY DEFICIENCY
5.9. GUILLAIN-BARRE SYNDROME
5.10. OTHER APPLICATIONS
6. GLOBAL IMMUNOGLOBULIN MARKET OUTLOOK – BY END-USER
6.1. HOSPITALS & CLINICS
6.2. HOMECARE
7. GLOBAL IMMUNOGLOBULIN MARKET OUTLOOK – BY SALES CHANNEL
7.1. HOSPITAL PHARMACY
7.2. SPECIALTY PHARMACY
7.3. OTHER SALES CHANNELS
8. GLOBAL IMMUNOGLOBULIN MARKET – REGIONAL OUTLOOK
8.1. NORTH AMERICA
8.1.1. MARKET BY TYPE
8.1.2. MARKET BY DELIVERY MODE
8.1.3. MARKET BY APPLICATION
8.1.4. MARKET BY END-USER
8.1.5. MARKET BY SALES CHANNEL
8.1.6. COUNTRY ANALYSIS
8.1.6.1. UNITED STATES
8.1.6.2. CANADA
8.2. EUROPE
8.2.1. MARKET BY TYPE
8.2.2. MARKET BY DELIVERY MODE
8.2.3. MARKET BY APPLICATION
8.2.4. MARKET BY END-USER
8.2.5. MARKET BY SALES CHANNEL
8.2.6. COUNTRY ANALYSIS
8.2.6.1. UNITED KINGDOM
8.2.6.2. GERMANY
8.2.6.3. FRANCE
8.2.6.4. SPAIN
8.2.6.5. ITALY
8.2.6.6. REST OF EUROPE
8.3. ASIA-PACIFIC
8.3.1. MARKET BY TYPE
8.3.2. MARKET BY DELIVERY MODE
8.3.3. MARKET BY APPLICATION
8.3.4. MARKET BY END-USER
8.3.5. MARKET BY SALES CHANNEL
8.3.6. COUNTRY ANALYSIS
8.3.6.1. CHINA
8.3.6.2. JAPAN
8.3.6.3. INDIA
8.3.6.4. SOUTH KOREA
8.3.6.5. ASEAN COUNTRIES
8.3.6.6. AUSTRALIA & NEW ZEALAND
8.3.6.7. REST OF ASIA-PACIFIC
8.4. LATIN AMERICA
8.4.1. MARKET BY TYPE
8.4.2. MARKET BY DELIVERY MODE
8.4.3. MARKET BY APPLICATION
8.4.4. MARKET BY END-USER
8.4.5. MARKET BY SALES CHANNEL
8.4.6. COUNTRY ANALYSIS
8.4.6.1. BRAZIL
8.4.6.2. MEXICO
8.4.6.3. REST OF LATIN AMERICA
8.5. MIDDLE EAST AND AFRICA
8.5.1. MARKET BY TYPE
8.5.2. MARKET BY DELIVERY MODE
8.5.3. MARKET BY APPLICATION
8.5.4. MARKET BY END-USER
8.5.5. MARKET BY SALES CHANNEL
8.5.6. COUNTRY ANALYSIS
8.5.6.1. UNITED ARAB EMIRATES
8.5.6.2. SAUDI ARABIA
8.5.6.3. TURKEY
8.5.6.4. SOUTH AFRICA
8.5.6.5. REST OF MIDDLE EAST & AFRICA
9. COMPETITIVE LANDSCAPE
9.1. BIOTEST AG
9.2. CHINA BIOLOGIC PRODUCTS INC
9.3. GRIFOLS SA
9.4. LFB GROUP
9.5. CSL BEHRING
9.6. KEDRION BIOPHARMA
9.7. OCTAPHARMA AG
9.8. TAKEDA PHARMACEUTICAL COMPANY LIMITED
9.9. BIO PRODUCTS LABORATORY
9.10. SHANGHAI RAAS BLOOD PRODUCTS CO LTD
9.11. PFIZER INC
9.12. SANQUIN PLASMA PRODUCTS BV
9.13. ADMA BIOLOGICS
9.14. SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD
9.15. KAMADA LTD
10. RESEARCH METHODOLOGY & SCOPE
10.1. RESEARCH SCOPE & DELIVERABLES
10.2. SOURCES OF DATA
10.3. RESEARCH METHODOLOGY

TABLE LIST
TABLE 1: GLOBAL IMMUNOGLOBULIN MARKET, BY REGIONAL OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: GLOBAL IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 4: GLOBAL IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 5: GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 6: GLOBAL IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 7: GLOBAL IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
TABLE 8: GLOBAL IMMUNOGLOBULIN MARKET, BY REGIONAL OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 9: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 10: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 11: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 12: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 13: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 14: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
TABLE 15: EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 16: EUROPE IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 17: EUROPE IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 18: EUROPE IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 19: EUROPE IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 20: EUROPE IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
TABLE 21: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 22: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 23: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 24: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 25: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 26: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
TABLE 27: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 28: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 29: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 30: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 31: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 32: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
TABLE 33: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 34: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 35: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 36: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 37: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 38: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
FIGURE LIST
FIGURE 1: MARKET ATTRACTIVENESS INDEX
FIGURE 2: GLOBAL IMMUNOGLOBULIN MARKET, BY TYPE, 2021 & 2028 (IN %)
FIGURE 3: GLOBAL IMMUNOGLOBULIN MARKET, BY IGG, 2022-2028 (IN $ MILLION)
FIGURE 4: GLOBAL IMMUNOGLOBULIN MARKET, BY IGA, 2022-2028 (IN $ MILLION)
FIGURE 5: GLOBAL IMMUNOGLOBULIN MARKET, BY IGM, 2022-2028 (IN $ MILLION)
FIGURE 6: GLOBAL IMMUNOGLOBULIN MARKET, BY IGE, 2022-2028 (IN $ MILLION)
FIGURE 7: GLOBAL IMMUNOGLOBULIN MARKET, BY IGD, 2022-2028 (IN $ MILLION)
FIGURE 8: GLOBAL IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2021 & 2028 (IN %)
FIGURE 9: GLOBAL IMMUNOGLOBULIN MARKET, BY INTRAVENOUS, 2022-2028 (IN $ MILLION)
FIGURE 10: GLOBAL IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS, 2022-2028 (IN $ MILLION)
FIGURE 11: GLOBAL IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR, 2022-2028 (IN $ MILLION)
FIGURE 12: GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, 2021 & 2028 (IN %)
FIGURE 13: GLOBAL IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2028 (IN $ MILLION)
FIGURE 14: GLOBAL IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2028 (IN $ MILLION)
FIGURE 15: GLOBAL IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2028 (IN $ MILLION)
FIGURE 16: GLOBAL IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2028 (IN $ MILLION)
FIGURE 17: GLOBAL IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2028 (IN $ MILLION)
FIGURE 18: GLOBAL IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2028 (IN $ MILLION)
FIGURE 19: GLOBAL IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2028 (IN $ MILLION)
FIGURE 20: GLOBAL IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2028 (IN $ MILLION)
FIGURE 21: GLOBAL IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2028 (IN $ MILLION)
FIGURE 22: GLOBAL IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2028 (IN $ MILLION)
FIGURE 23: GLOBAL IMMUNOGLOBULIN MARKET, BY END-USER, 2021 & 2028 (IN %)
FIGURE 24: GLOBAL IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2028 (IN $ MILLION)
FIGURE 25: GLOBAL IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2028 (IN $ MILLION)
FIGURE 26: GLOBAL IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2021 & 2028 (IN %)
FIGURE 27: GLOBAL IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2028 (IN $ MILLION)
FIGURE 28: GLOBAL IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2028 (IN $ MILLION)
FIGURE 29: GLOBAL IMMUNOGLOBULIN MARKET, BY OTHER SALES CHANNELS, 2022-2028 (IN $ MILLION)
FIGURE 30: GLOBAL IMMUNOGLOBULIN MARKET, REGIONAL OUTLOOK, 2021 & 2028 (IN %)
FIGURE 31: UNITED STATES IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 32: CANADA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 33: UNITED KINGDOM IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 34: GERMANY IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 35: FRANCE IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 36: SPAIN IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 37: ITALY IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 38: REST OF EUROPE IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 39: CHINA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 40: JAPAN IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 41: INDIA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 42: SOUTH KOREA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 43: ASEAN COUNTRIES IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 44: AUSTRALIA & NEW ZEALAND IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 45: REST OF ASIA-PACIFIC IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 46: BRAZIL IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 47: MEXICO IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 48: REST OF LATIN AMERICA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 49: UNITED ARAB EMIRATES IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 50: SAUDI ARABIA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 51: TURKEY IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 52: SOUTH AFRICA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)
FIGURE 53: REST OF MIDDLE EAST & AFRICA IMMUNOGLOBULIN MARKET 2022-2028 (IN $ MILLION)

ページTOPに戻る

図表リスト

TABLE LIST
TABLE 1: GLOBAL IMMUNOGLOBULIN MARKET, BY REGIONAL OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: GLOBAL IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 4: GLOBAL IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 5: GLOBAL IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 6: GLOBAL IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 7: GLOBAL IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
TABLE 8: GLOBAL IMMUNOGLOBULIN MARKET, BY REGIONAL OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 9: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 10: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 11: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 12: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 13: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 14: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
TABLE 15: EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 16: EUROPE IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 17: EUROPE IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 18: EUROPE IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 19: EUROPE IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 20: EUROPE IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
TABLE 21: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 22: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 23: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 24: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 25: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 26: ASIA-PACIFIC IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
TABLE 27: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 28: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 29: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 30: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 31: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 32: LATIN AMERICA IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)
TABLE 33: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY COUNTRY OUTLOOK, 2022-2028 (IN $ MILLION)
TABLE 34: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY TYPE, 2022-2028 (IN $ MILLION)
TABLE 35: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY DELIVERY MODE, 2022-2028 (IN $ MILLION)
TABLE 36: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY APPLICATION, 2022-2028 (IN $ MILLION)
TABLE 37: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY END-USER, 2022-2028 (IN $ MILLION)
TABLE 38: MIDDLE EAST AND AFRICA IMMUNOGLOBULIN MARKET, BY SALES CHANNEL, 2022-2028 (IN $ MILLION)